Zobrazeno 1 - 10
of 58
pro vyhledávání: '"R I Stryuk"'
Autor:
R I Stryuk, C A Burns, M P Filippov, Ya V Brytkova, I V Borisov, E L Barkova, T A Gomova, E A Kozina, O A Nagirnyak
Publikováno v:
Терапевтический архив, Vol 90, Iss 1, Pp 9-16 (2018)
The Aim of the BEREG Registry was to analyze the prevalence and structure of cardiovascular diseases, associated comorbid conditions and assess their effects on pregnancy and perinatal outcomes in real clinical practice.In Tula city regional perinata
Externí odkaz:
https://doaj.org/article/27fc032bde8a4ed1ba4e72e2d7c5e17f
Publikováno v:
Терапевтический архив, Vol 89, Iss 3, Pp 65-71 (2017)
Aim. To investigate factors that influence annual prognosis in patients with non-ST-segment elevation acute coronary syndrome ((NSTEACS) concurrent with type 2 diabetes mellitus (DM2). Subjects and methods. The registry of patients with NSTEACS (non-
Externí odkaz:
https://doaj.org/article/81f3bfe080de40738c19e5883d0d7ecf
Publikováno v:
Системные гипертензии, Vol 8, Iss 2, Pp 28-32 (2011)
Externí odkaz:
https://doaj.org/article/50be24471c634580a4a7ba3265943366
Autor:
R I Stryuk
Publikováno v:
Системные гипертензии, Vol 6, Iss 2, Pp 31-34 (2009)
Externí odkaz:
https://doaj.org/article/997f89d2fb974fa2b987f95dc2975028
Autor:
R I Stryuk
Publikováno v:
Системные гипертензии, Vol 7, Iss 3, Pp 27-29 (2010)
Externí odkaz:
https://doaj.org/article/c42a47826254489cbb26fbd094c2e585
Autor:
O. B. Irtyuga, R. G. Shmakov, Y. V. Vavilova, I. E. Zazerskaya, Z. S. Khodzhaeva, V. K. Lebedeva, R. I. Stryuk
Publikováno v:
Российский кардиологический журнал, Vol 28, Iss 4 (2023)
On December 18, 2022, an interdisciplinary Expert Council was held in St. Petersburg, dedicated to the debatable issues of anticoagulation in the prevention of venous thromboembolism in pregnant women with cardiovascular and systemic diseases, at
Externí odkaz:
https://doaj.org/article/3c9f0330c11842868e09638b4295092f
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 17, Iss 4, Pp 638-641 (2021)
The main stages of the creative path of the scientist with a world-famous, professor, the Honored Worker of Science of the Russian Federation, Academician of the Russian Academy of Sciences Alexey Petrovich Golikov are presented in the article.
Externí odkaz:
https://doaj.org/article/0aa7930ee830417f8be347d2ea899855
Autor:
O. D. Ostroumova, A. I. Kochetkov, F. T. Ageev, G. S. Anikin, E. Kh. Akhmetzyanova, E. I. Bezuglova, A. B. Bekoeva, N. Yu. Borovkova, N. G. Vinogradova, E. V. Gorbunova, A. A. Goryacheva, E. S. Zhugrova, O. A. Kislyak, S. M. Klyashev, V. P. Kuzmin, A. A. Lipchenko, G. V. Matyushin, E. A. Mikhailova, V. A. Nevzorova, A. G. Obrezan, T. A. Petrichko, M. M. Petrova, A. N. Reider, A. N. Repin, V. I. Sadovoy, N. P. Sanina, A. E. Skripchenko, R. I. Stryuk, I. V. Faiyance, L. A. Khaisheva, N. R. Khasanov, R. A. Khokhlov, E. E. Tsareva, A. L. Cherkashina, I. I. Shaposhnik, I. A. Shelestova, R. N. Shepel, E. V. Shikh, D. A. Yakhontov
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 16, Iss 2, Pp 175-190 (2020)
Aim. To evaluate the effectiveness and safety of telmisartan, used in monotherapy or in combination with hydrochlorothiazide or amlodipine, in real clinical practice in patients with diagnosed arterial hypertension who have not reached the target lev
Externí odkaz:
https://doaj.org/article/9a89b6f41c844d00b164e671e6fe74c3
Publikováno v:
Meditsinskiy sovet = Medical Council. :24-32
Introdiction. The article highlights the importance of optimizing the treatment of chronic heart failure (CHF) in patients with comorbid cardiopulmonary pathology, namely ischemic heart disease (CHD) in combination with chronic obstructive pulmonary
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0668c885195fe90518648d7bd43ce35e
https://doi.org/10.21518/2079-701x-2022-16-23-24-32
https://doi.org/10.21518/2079-701x-2022-16-23-24-32
Autor:
O. V. Krikunova, R. I. Stryuk
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 14, Iss 1, Pp 131-136 (2018)
Anticoagulant therapy is widely used in all forms of acute coronary syndrome (ACS) to inhibit the formation of thrombin and/or to inhibit its activity to reduce the risk of thrombotic events (both in primary percutaneous coronary intervention and in
Externí odkaz:
https://doaj.org/article/5da9a6976c1d4ed7bf315780e2f8a5c4